Search

News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice

At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.

Source: Intestinal Inflammations 20. 9. 2023

News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.

Source: Thromboprophylaxis 28. 11. 2023

News Safety of Metamizole in Adult Patients –⁠ Meta-analysis of 79 Studies

Metamizole is a non-opioid analgesic with antipyretic and spasmolytic effects that has been used for over 100 years. It is approved for the treatment of children and adults in various dosage forms. German authors conducted a systematic literature review and meta-analysis of clinical studies to evaluate its safety compared to placebo and other analgesics in adult patients.

Source: Analgesia 30. 5. 2024

News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function -⁠ Findings from a Recent Meta-analysis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.

Source: Heart Failure 3. 11. 2022

News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice

Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?

Source: Cough Therapy 15. 2. 2022

News Romiplostim in Newly Diagnosed or Persistent ITP

Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly diagnosed immune thrombocytopenia (ITP) or persistent ITP who have failed treatment with corticosteroids or intravenous immunoglobulins. The rationale for these recommendations is documented in a paper whose authors focus on, among other things, the American Society of Hematology (ASH) 2019 guidelines or the European ITP Working Group guidelines. They also summarized published data from clinical trials, real-world practice, etc., regarding the use of the TPO-RA romiplostim in earlier phases of ITP therapy.

Source: Immune Thrombocytopenia 21. 2. 2023

News Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Antibodies against the programmed cell death protein 1 (PD-1) improve the survival of patients with advanced non-small cell lung cancer (NSCLC). However, their use has not yet been tested in patients with resectable NSCLC. In 2018, the New England Journal of Medicine published the results of a pilot study of neoadjuvant therapy with nivolumab in patients with resectable NSCLC. Based on the promising results of this study, the investigative team subsequently decided to also test a combination of nivolumab and ipilimumab.

Source: Immunotherapy in Oncology 6. 11. 2020

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.

Source: Oncological Treatment 22. 11. 2021

News Impact of Early Administration of High Protein Dose on Mortality of Critically Ill Patients

Energy intake and the composition of individual macronutrients in patients in intensive care units (ICUs) can influence treatment outcomes in terms of the incidence of complications, duration of mechanical ventilation, or mortality.

Source: Parenteral Nutrition 14. 11. 2022

News Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients

Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody against IL-17A and IL-17F, bimekizumab, in patients with plaque psoriasis using a prefilled syringe or autoinjector.

Source: Psoriasis 3. 6. 2022

News Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol

A newly published study by authors from Singapore focused on the ability of the SEP protocol –⁠ short-term low-dose enoxaparin administration based on body weight –⁠ to maintain the patency of an arteriovenous (A-V) shunt after recurrent thrombosis.

Source: Thromboprophylaxis 3. 1. 2024

News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy

The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.

Source: Arthritis 8. 6. 2023

News Study AMPLIFY Confirmed Safety and Efficacy of Fixed Combination Aclidinium/Formoterol in COPD Therapy

The randomized double-blind phase III AMPLIFY study compared the efficacy of a fixed combination of formoterol/aclidinium with monotherapy of the individual components or with tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Source: Treatment of Asthma and COPD 15. 7. 2020

News Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate

The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA) inadequately controlled by methotrexate demonstrated the benefit of adding baricitinib or adalimumab compared to placebo in terms of reducing the number of swollen joints. However, baricitinib showed greater pain relief starting from week 1 compared to placebo and from week 2 compared to adalimumab. Thus, the recently published results of an analysis using the data from this study aimed to compare the proportion of patients who achieved certain pain relief thresholds, the time required for pain relief, and the relationship between the presence of inflammation and pain.

Source: Biological Treatment 17. 2. 2020

News When to Initiate Dabigatran Therapy in Patients with Atrial Fibrillation After First Ischemic Stroke?

After a cardioembolic ischemic stroke (iCMP), approximately 5% of patients experience a recurrence within the first 14 days without anticoagulant therapy. The aim of the retrospective observational study presented below was to evaluate the optimal timing of initiating dabigatran anticoagulant therapy with respect to the risk of intracerebral hemorrhage.

Source: Anticoagulant Treatment 21. 7. 2020